<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078803</url>
  </required_header>
  <id_info>
    <org_study_id>66218</org_study_id>
    <nct_id>NCT03078803</nct_id>
  </id_info>
  <brief_title>Fecal Transplant for Crohn's Disease</brief_title>
  <official_title>A Prospective Multicenter Randomized Controlled Trial Comparing Fecal Microbiota Transplantation (FMT) to Placebo in the Treatment of Mild to Moderate Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of serial FMT at inducing and maintaining clinical and
      endoscopic response in patients with mild to moderate Crohn's disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind study will randomize patients with mild to moderate Crohn's 1:1 (FMT : water)
      stratified by disease duration and current use of biologic therapy. First FMT/placebo at week
      0 by colonoscopy plus weekly FMT/placebo by capsules for 7 weeks. At week 8, a repeat
      colonoscopy will be done and endoscopy score repeated.

      Responders in FMT arm are eligible to enter open label phase to receive FMT by capsules q2
      weeks.

      Blood, stool and urine samples, colonic biopsies will be collected. Quality of Life as
      measured by Short Inflammatory Bowel Disease Questionnaire, EuroQol five dimensions, and Work
      Productivity and Activity Impairment Questionnaire: Crohns disease and dietary intake diary
      collected.

      Colonoscopies recorded and reviewed by a central reader.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and Endoscopic Remission</measure>
    <time_frame>Week 8</time_frame>
    <description>Harvey Bradshaw Index &lt;5 and Simple endoscopic score &lt;5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Week 8</time_frame>
    <description>Harvey Bradshaw Index reduction by 3 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>Week 8</time_frame>
    <description>Harvey Bradshaw Index &lt;5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic response</measure>
    <time_frame>Week 8</time_frame>
    <description>Simple endoscopic score reduction by 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission</measure>
    <time_frame>Week 8</time_frame>
    <description>Simple endoscopic score &lt;5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life 1</measure>
    <time_frame>Week 8</time_frame>
    <description>Mean changes in Short Inflammatory Bowel Disease Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life 2</measure>
    <time_frame>Week 8</time_frame>
    <description>Mean changes in Euro five dimensions questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life 3</measure>
    <time_frame>Week 8</time_frame>
    <description>Mean changes in Work Productivity and Activity Impairment: Crohns Disease questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Fecal microbiota transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfer of healthy human gut bacteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Water</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplant (FMT)</intervention_name>
    <description>FMT delivered by colonoscopy and oral capsules</description>
    <arm_group_label>Fecal microbiota transplant</arm_group_label>
    <other_name>FMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Transfer of water only</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mild to moderate ileo-colonic or colonic Crohns disease

          -  active colonic inflammation with either elevated C-reactive protein &gt;8mg/L or elevated
             fecal calprotectin &gt;250 ug/g

          -  If applicable, meds stable as follows: 5-ASA for 4 weeks, prednisone up to 20mg QD for
             4 weeks, budesonide up to 6mg QD for 4 weeks, azathioprine, 6-MP and methotrexate for
             12 weeks

          -  Use of effective contraception

        Exclusion Criteria:

          -  Antibiotic exposure within 30 days

          -  topical inflammatory bowel disease therapy within 2 weeks

          -  active perianal disease

          -  requirement for concurrent antibiotic therapy

          -  severe CD HBI &gt;25 or need for hospitalization

          -  abdominal abscess

          -  extensive colonic resection, subtotal or total colectomy

          -  ileostomy, colostomy, known fixed symptomatic stenosis or complex fistulae

          -  evidence of or treatment for C. difficile or other intestinal pathogen including
             Cytomegalovirus within 28 days

          -  requiring or expected to require surgical intervention

          -  history or evidence of adenomatous colonic polyps not removed

          -  history of evidence of colonic dysplasia

          -  active substance abuse or psychiatric problems that may interfere with study

          -  chronic Hep B, C, or HIV infection

          -  pregnancy or planning to become pregnant

          -  upper CD

          -  history of adhesions preventing colonoscopy to cecum

          -  planned bowel resection within 3 mon of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina Kao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dina Kao, MD</last_name>
    <phone>780 492 8307</phone>
    <email>dkao@ualberta.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina Kao, MD</last_name>
      <phone>780 492 8307</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fecal transplant</keyword>
  <keyword>inflammatory bowel disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

